The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Prognostic impact of early treatment discontinuation and early oxaliplatin discontinuation in patients treated with 6 months of oxaliplatin-based adjuvant chemotherapy for stage III colon cancer: an ACCENT/IDEA pooled analysis of 11 trials.
 
Claire Gallois
Travel, Accommodations, Expenses - Amgen
 
Qian Shi
Stock and Other Ownership Interests - Amgen; Johnson & Johnson; Merck
Honoraria - Chugai Pharma
Consulting or Advisory Role - Boehringer Ingelheim; Hoosier Cancer Research Network; Regeneron; Yiviva
Research Funding - BMS (Inst); Celgene (Inst); Janssen (Inst); Novartis (Inst); Roche/Genentech (Inst)
 
Jeffrey P. Meyers
No Relationships to Disclose
 
Timothy Iveson
Honoraria - Amgen; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; MSD Oncology; Pierre Fabre; SERVIER
 
Steven R Alberts
No Relationships to Disclose
 
Aimery De Gramont
No Relationships to Disclose
 
Alberto F. Sobrero
Stock and Other Ownership Interests - Bayer
Consulting or Advisory Role - Amgen; Bayer; Celgene; Menarini; Merck Serono; Roche; Sanofi; SERVIER
Speakers' Bureau - amgen; AstraZeneca; Bayer; Bristol-Myers Squibb; celgene; Lilly; Merck Serono; Roche; Sanofi; Takeda
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche; Takeda
 
Daniel G. Haller
Speakers' Bureau - Amgen; Exelixis; Lilly; Taiho Pharmaceutical
 
Eiji Oki
Speakers' Bureau - Bayer Yakuhin; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Ono Pharmaceutical; Takeda
 
Anthony Frank Shields
Consulting or Advisory Role - Caris Life Sciences; ImaginAb
Speakers' Bureau - Caris Life Sciences
Research Funding - Alkermes; Astellas Pharma; AstraZeneca; Bayer; Boehringer Ingelheim; Boston Biomedical; Caris Life Sciences; Daiichi Sankyo; Eisai; Esperas Pharma; Esperas Pharma; Exelixis; Five Prime Therapeutics; H3 Biomedicine; Halozyme; Hutchison China Meditech; ImaginAb; Incyte; Inovio Pharmaceuticals; Jiangsu Alphamab Biopharmaceuticals; Lexicon; LSK BioPharma; MSK Pharma; Nouscom; Plexxikon; Repertoire Immune Medicines; Seagen; Shanghai HaiHe Pharmaceutical; Taiho Pharmaceutical; Telix Pharmaceuticals; TopAlliance BioSciences Inc (Inst); Xencor
Travel, Accommodations, Expenses - Caris Life Sciences; GE Healthcare; ImaginAb; Inovio Pharmaceuticals; TransTarget
 
Caroline Kelly
No Relationships to Disclose
 
Ioannis Boukovinas
Employment - Pierre Fabre (I)
Honoraria - AstraZeneca; Bristol-Myers Squibb; LEO Pharma; Merck; MSD; Novartis; Pfizer; Roche; SERVIER
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Genesis Pharma; Ipsen; LEO Pharma; MSD; Novartis; Roche; Sanofi
Research Funding - Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Pfizer; Regeneron; Roche
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Ipsen; MSD; Pfizer; Roche; Servier
 
Roberto Labianca
Consulting or Advisory Role - Lilly; Merck Serono; Roche; Sanofi
Travel, Accommodations, Expenses - Merck Serono; Roche; SERVIER
 
Frank A. Sinicrope
Stock and Other Ownership Interests - illumina
Honoraria - American Society of Clinical Oncology; Imedex
Consulting or Advisory Role - Bristol-Myers Squibb (Inst); HalioDx (Inst); Roche (Inst); Ventana Medical Systems (Inst)
Research Funding - Ventana Medical Systems (Inst)
Patents, Royalties, Other Intellectual Property - Patent royalty related to immune markers in colon cancer. Patent jointly held between myself and Roche/Ventana Medical Systems. (Inst)
Travel, Accommodations, Expenses - ventana medical systems
 
Ioannis Sougklakos
Consulting or Advisory Role - Bristol-Myers Squibb-Ono Pharmaceutical; IPSEN (Inst); MSD; Pierre Fabre; Roche (Inst); SERVIER (Inst)
Speakers' Bureau - Merck KGaA (Inst); MSD; Roche (Inst); Sanofi
Research Funding - Amgen (Inst); Sanofi (Inst)
Travel, Accommodations, Expenses - Amgen; Merck Serono; Roche; Sanofi; SERVIER
 
Takayuki Yoshino
Honoraria - Bayer Yakuhin; Chugai Pharma; Lilly; Merck; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Amgen (Inst); Chugai Pharma (Inst); DAIICHI SANKYO COMPANY, LIMITED (Inst); MSD (Inst); Ono Pharmaceutical (Inst); PAREXEL International Inc. (Inst); Sanofi (Inst); Taiho Pharmaceutical (Inst)
 
Jeffrey A. Meyerhardt
Honoraria - Cota Healthcare; Taiho Pharmaceutical
Research Funding - Boston Biomedical (Inst)
 
Thierry Andre
Honoraria - AMGEN; Bristol-Myers Squibb; GlaxoSmithKline; Pierre Fabre; Roche/Genentech; SERVIER; Ventana Medical Systems
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; GamaMabs Pharma; GlaxoSmithKline; Gritstone Bio; Kaleido Biosciences; MSD Oncology; Pierre Fabre; Seagen; SERVIER; Tesaro; Transgene
Travel, Accommodations, Expenses - MSD Oncology
 
Demetris Papamichail
Consulting or Advisory Role - Merck; Novartis; Sanofi
Speakers' Bureau - Amgen; Merck; Roche
Research Funding - MSD
Travel, Accommodations, Expenses - Merck; MSD
 
Julien Taieb
Consulting or Advisory Role - Amgen; Merck KGaA; MSD; Novartis; Pierre Fabre; Roche; SERVIER
Speakers' Bureau - Amgen; Lilly; Merck; MSD; Pierre Fabre; Roche/Genentech; Sanofi; SERVIER